StockNews.com upgraded shares of Smith & Nephew (NYSE:SNN – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Wednesday morning.
Several other brokerages have also commented on SNN. Deutsche Bank Aktiengesellschaft lowered Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Canaccord Genuity Group reiterated a “hold” rating and set a $27.00 target price on shares of Smith & Nephew in a research report on Wednesday. Finally, Berenberg Bank lowered Smith & Nephew from a “buy” rating to a “hold” rating in a report on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $27.00.
Get Our Latest Stock Analysis on SNN
Smith & Nephew Stock Up 2.9 %
Institutional Investors Weigh In On Smith & Nephew
A number of institutional investors and hedge funds have recently bought and sold shares of SNN. Principal Securities Inc. increased its stake in shares of Smith & Nephew by 87.6% during the 4th quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 691 shares during the last quarter. R Squared Ltd purchased a new stake in shares of Smith & Nephew in the fourth quarter worth about $41,000. National Bank of Canada FI grew its position in Smith & Nephew by 36.5% in the fourth quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider’s stock valued at $41,000 after acquiring an additional 446 shares in the last quarter. Hara Capital LLC grew its position in Smith & Nephew by 391.4% in the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider’s stock valued at $60,000 after acquiring an additional 1,957 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Smith & Nephew by 31.8% during the fourth quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider’s stock valued at $73,000 after purchasing an additional 718 shares during the period. Hedge funds and other institutional investors own 25.64% of the company’s stock.
About Smith & Nephew
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.
Read More
- Five stocks we like better than Smith & Nephew
- What is diluted earnings per share (Diluted EPS)?
- Buffett’s on the Sidelines – Should You Follow?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.